CAR T-Cell Therapy Market to Reach $35.9 Billion by 2032 At A 28.5% CAGR: Allied Market Research

Rise in prevalence of leukemia, surge in research and development activities to develop new CAR T-cell therapy are the key factors driving the growth of the market for CAR T-cell therapy.

Wilmington, New Castle,  Delaware, Jan. 25, 2024 (GLOBE NEWSWIRE) — Allied Market Research published a report, titled,CAR T-Cell Therapy Market Size, Share, Competitive Landscape and Trend Analysis Report by Drug type (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel, Others), by Indication (Lymphoma, Acute Lymphocytic Leukemia, Others), by End user (Hospitals, Cancer Treatment Centers): Global Opportunity Analysis and Industry Forecast, 2023-2032“. According to the report, the CAR T-cell therapy industry generated $2.6 billion in 2022, and is anticipated to generate $35.9 billion by 2032, witnessing a CAGR of 28.5% from 2023 to 2032.  

Prime determinants of growth  

Surge in prevalence of cancer, high effectivity of CAR T-cell therapy over other conventional drugs for cancer treatment and increase in investment and funding for research in CAR T-Cell therapy are the major factors that drive the growth of the CAR T-cell therapy market. However, high cost of CAR T-cell therapy restricts market growth. Moreover, high research and development activities to develop CAR T-cell therapeutics presents new opportunities in the coming years.  

Request Sample of the Report on CAR T-Cell Therapy Market Forecast 2032 – https://www.alliedmarketresearch.com/request-sample/A16971 

Report Coverage & Details: 

Report Coverage  Details 
Forecast Period  2023–2032 
Base Year  2022 
Market Size in 2022  $2.6 billion 
Market Size in 2032  $35.9 billion 
CAGR  28.5% 
No. of Pages in Report  219 
Segments covered  Drug Type, Indication, End User and Region 
Drivers   Surge in prevalence of cancer.  
High effectivity of CAR T-cell therapy over other conventional drugs for cancer treatment. 
Increase in investment and funding for research in CAR T-Cell therapy. 
Opportunities  High R&D activities to develop CAR T-cell therapeutics.  
Restraint  High cost of CAR T-cell therapies. 

Recession Impact 

  • During recession, there might be a decrease in research funding, both from government sources and private institutions. This reduction in funding could lead to a slowdown in research projects involving CAR T-cell therapy, as researchers may have fewer resources to invest in their studies. 
  • In addition, recessions lead to disruptions in supply chains, affecting the availability of necessary materials and resources for research. This could lead to delays in projects and increased costs. 
  • However, surge in adoption of CAR T-cell therapy, and increase in cases of cancer are anticipated to drive the market growth in the coming future. 

Want to Explore More, Connect to our Analyst – https://www.alliedmarketresearch.com/connect-to-analyst/A16971 

The axicabtagene ciloleucel segment to maintain its leadership status throughout the forecast period 

Based on drug type, the axicabtagene ciloleucel segment held the highest market share in 2022, accounting for more than two fifth of CAR T-cell therapy market revenue, owing to high adoption of axicabtagene ciloleucel for the treatment of adult patients with large B-cell lymphoma. 

The lymphoma segment to maintain its leadership status throughout the forecast period 

Based on indication, the lymphoma segment held the highest market share in 2022, accounting for more than half of CAR T-cell therapy market revenue. This is attributed to high prevalence of lymphoma globally. However, other segment is expected to register fastest growth during the forecast period, owing to high research to explore various other therapeutic application of CAR T-cell therapy. 

The hospital segment to maintain its leadership status throughout the forecast period 

Based on end user, the hospital segment held the highest market share in 2022, accounting for four fifth of CAR T-cell therapy market revenue. This is attributed to high number of patients getting cancer treatment in the hospital.  

For Procurement Information – https://www.alliedmarketresearch.com/purchase-enquiry/A16971 

North America to maintain its dominance by 2032  

Based on region, North America held the largest market share in terms of revenue in 2022, accounting for more than three fifth of the CAR T-cell therapy market revenue. This is attributed to strong presence of key players in the region   

However, the Europe region is expected to witness the fastest CAGR of 30.3% from 2023 to 2032. This is attributed to prevalence rate of cancer, a large and diverse population, and well-developed healthcare infrastructure. 

Leading Market Players: –

  • Autolus Theraputics Plc  
  • 2Seventy Bio, Inc  
  • Bristol-Myers Squibb 
  • Gilead Sciences 
  • Intellia Therapeutics 
  • Caribou Biosciences, Inc. 
  • Cartesian Therapeutics, Inc  
  • Novartis AG 
  • Pfizer 
  • Johnson and Johnson.  

The report provides a detailed analysis of these key players in the CAR T-Cell Therapy Market. These players have adopted different strategies such as product approvals, collaboration, clinical trials, strategic alliance and merger to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.   

Comprehensive Healthcare Industry Research Studies: – 

Internet of Things in Healthcare Market- Global Opportunity Analysis and Industry Forecast, 2022–2032 

Medical Tourism Market- Global Opportunity Analysis and Industry Forecast, 2022–2032 

3D Cell Culture Market- Global Opportunity Analysis and Industry Forecast, 2022–2032 

Neurovascular Devices Market- Global Opportunity Analysis and Industry Forecast, 2022–2032 

Viral Vector and Plasmid DNA Manufacturing Market- Global Opportunity Analysis and Industry Forecast, 2022–2032 

About Allied Market Research: 

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI. 

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.  

Contact 
David Correa 

1209 Orange Street, 

Corporation Trust Center, 

Wilmington, New Castle, 

Delaware 19801 USA. 

Toll Free: +1-800-792-5285 

Int’l: +1-503-894-6022 

UK: +44-845-528-1300 

Hong Kong: +852-301-84916 

India (Pune): +91-20-66346060 

Fax: +1-855-550-5975 

help@alliedmarketresearch.com   

Web: https://www.alliedmarketresearch.com   

Follow Us on: LinkedIn Twitter 

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.